Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 31 to 33 of 33 results for ibrutinib

  1. Ibrutinib for treating Waldenstrom's macroglobulinaemia (TA491)

    This guidance has been updated and replaced by NICE technology appraisal guidance 795.

    Technology appraisal guidance
    Published
    22 November 2017

  2. Idelalisib with bendamustine and rituximab for previously treated chronic lymphocytic leukaemia [ID839]

    Discontinued Reference number: GID-TA10109

    Technology appraisal guidance
    Discontinued

  3. Ibrutinib for treating relapsed or refractory follicular lymphoma and marginal zone lymphoma [ID1251]

    Discontinued Reference number: GID-TA10525

    Technology appraisal guidance
    Discontinued